The use of cholesterol (1%) with HFD in DIOs was found to aggravate NASH and the severity of MAFLD in multiple parameters with exacerbated weight gain, hepatic steatosis and fibrosis, and serum ALT [213]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.